{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:00:15Z","timestamp":1794474015737,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic myeloid leukemia (CML) is a chronic condition with excellent long-term survival under tyrosine kinase inhibitor (TKI) therapy. However, patient priorities regarding treatment goals and quality of life remain insufficiently understood. We conducted a nationwide online survey among German CML patients in collaboration with the German CML Alliance and patient organizations to assess treatment goals at diagnosis, during therapy, and in the treatment-free remission phase. The questionnaire included validated measures of treatment satisfaction, fear of progression, and quality-of-life priorities, supplemented by newly developed items. Between November 2024 and February 2025, 582 patients (median age 56 years, 48.8% female) completed the survey. Overall TKI tolerability was rated positively (median 4\/5), particularly in first-line therapy and among patients with shorter disease duration, whereas long-term survivors reported more daily-life limitations. Younger patients (\u2009&lt;\u200945 years) emphasized fertility, sexuality, and work-related concerns, while older patients prioritized tolerability, independence, and mental health. Treatment history shaped expectations: those with discontinuation experience were more willing to accept adverse effects for the prospect of remission. Overall, patient priorities diverged between achieving deep molecular response and maintaining optimal tolerability. Integrating patient-reported preferences into shared decision-making may enhance satisfaction, adherence, and long-term outcomes of patients with CML.<\/jats:p>","DOI":"10.1038\/s41375-025-02826-w","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:49:54Z","timestamp":1766126994000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5165-9874","authenticated-orcid":false,"given":"Philipp","family":"Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cera","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-7127","authenticated-orcid":false,"given":"Michael","family":"Lauseker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Gei\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-5785","authenticated-orcid":false,"given":"Susanne","family":"Sau\u00dfele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-8844","authenticated-orcid":false,"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-002X","authenticated-orcid":false,"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-7809","authenticated-orcid":false,"given":"Paul","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-7592","authenticated-orcid":false,"given":"Annamaria","family":"Brioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fabisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-489X","authenticated-orcid":false,"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Mehlkop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2826_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101405","volume":"47","author":"SA Alessy","year":"2022","unstructured":"Alessy SA, Alhajji M, Rawlinson J, Baker M, Davies EA. Factors influencing cancer patients\u2019 experiences of care in the USA, United Kingdom, and Canada: a systematic review. EClinicalMedicine. 2022;47:101405.","journal-title":"EClinicalMedicine"},{"key":"2826_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6955-8-1","volume":"8","author":"ER Posma","year":"2009","unstructured":"Posma ER, van Weert JCM, Jansen J, Bensing JM. Older cancer patients\u2019 information and support needs surrounding treatment: an evaluation through the eyes of patients, relatives and professionals. BMC Nurs. 2009;8:1.","journal-title":"BMC Nurs"},{"key":"2826_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lisr.2005.11.003","volume":"28","author":"K Ankem","year":"2006","unstructured":"Ankem K. Factors influencing information needs among cancer patients: a meta-analysis. Libr Inf Sci Res. 2006;28:7\u201323.","journal-title":"Libr Inf Sci Res"},{"key":"2826_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1369-7625.2010.00598.x","volume":"14","author":"P Ormandy","year":"2011","unstructured":"Ormandy P. Defining information need in health - assimilating complex theories derived from information science. Health Expect. 2011;14:92\u2013104.","journal-title":"Health Expect"},{"key":"2826_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood-2023-182792","volume":"142","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Mayer J, Br\u00fcmmendorf TH, et al. Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial. Blood. 2023;142:446.","journal-title":"Blood"},{"key":"2826_CR6","unstructured":"SEER Stat Fact Sheets: Chronic Myeloid Leukemia. Surveillance, Epidemiology and End Results (SEER), SEER 22 2017\u20132021, All Races, Both Sexes. accessed on 23rd March 2025."},{"key":"2826_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"2826_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2826_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.631570","volume":"11","author":"M Breccia","year":"2021","unstructured":"Breccia M, Abruzzese E, Annunziata M, Luciano L, Sica S. Clinical and psychological factors to consider in achieving treatment-free remission in patients with chronic myeloid leukemia. Front Oncol. 2021;11:631570.","journal-title":"Front Oncol"},{"key":"2826_CR10","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood.2020006911","volume":"136","author":"J Cortes","year":"2020","unstructured":"Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136:2507\u201312.","journal-title":"Blood"},{"key":"2826_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","volume":"143","author":"J Geissler","year":"2017","unstructured":"Geissler J, Sharf G, Bombaci F, Daban M, De Jong J, Gavin T, et al. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol. 2017;143:1167\u201376.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2826_CR12","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648\u201371.","journal-title":"Leukemia"},{"key":"2826_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3324\/haematol.2013.094045","volume":"99","author":"M Baccarani","year":"2014","unstructured":"Baccarani M, Efficace F, Rosti G. Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica. 2014;99:205\u20138.","journal-title":"Haematologica"},{"key":"2826_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1524-4733.2007.00310.x","volume":"11","author":"PC Trask","year":"2008","unstructured":"Trask PC, Tellefsen C, Espindle D, Getter C, Hsu MA. Psychometric validation of the cancer therapy satisfaction questionnaire. Value Health. 2008;11:669\u201379.","journal-title":"Value Health"},{"key":"2826_CR15","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1111\/j.1524-4733.2005.00073.x","volume":"8","author":"L Abetz","year":"2005","unstructured":"Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-Maynard D, et al. Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing. Value Health. 2005;8:S41\u201353.","journal-title":"Value Health"},{"key":"2826_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jpsychores.2005.02.007","volume":"58","author":"P Herschbach","year":"2005","unstructured":"Herschbach P, Berg P, Dankert A, Duran G, Engst-Hastreiter U, Waadt S, et al. Fear of progression in chronic diseases: psychometric properties of the Fear of Progression Questionnaire. J Psychosom Res. 2005;58:505\u201311.","journal-title":"J Psychosom Res"},{"key":"2826_CR17","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1002\/cncr.32961","volume":"126","author":"CP Williams","year":"2020","unstructured":"Williams CP, Miller-Sonet E, Nipp RD, Kamal AH, Love S, Rocque GB. Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians. Cancer. 2020;126:3534\u201341.","journal-title":"Cancer"},{"key":"2826_CR18","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","volume":"34","author":"G Sharf","year":"2020","unstructured":"Sharf G, Marin C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34:2102\u201312.","journal-title":"Leukemia"},{"key":"2826_CR19","first-page":"88","volume":"6","author":"Robert Koch-Institut","year":"2021","unstructured":"Robert Koch-Institut. Fragebogen zur Studie Gesundheit in Deutschland aktuell: GEDA 2019\/2020-EHIS. J Health Monit. 2021;6:88\u2013106.","journal-title":"J Health Monit"},{"key":"2826_CR20","unstructured":"Stiftung Gesundheitswissen. Health Information National Trends Survey (HINTS) Germany, Welle 1 [Fragebogen]. 2020."},{"key":"2826_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/10810730.2022.2134522","volume":"27","author":"E Link","year":"2022","unstructured":"Link E, Baumann E, Kreps GL, Czerwinski F, Rosset M, Suhr R. Expanding the Health Information National Trends Survey Research Program Internationally to Examine Global Health Communication Trends: Comparing Health Information Seeking Behaviors in the U.S. and Germany. J Health Commun. 2022;27:545\u201354.","journal-title":"J Health Commun"},{"key":"2826_CR22","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed Hillsdale, NJ: Lawrence Erlbaum Associates. 1988."},{"key":"2826_CR23","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118:4554\u201360.","journal-title":"Blood"},{"key":"2826_CR24","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S2152-2650(25)00312-X","volume":"25","author":"KE Flynn","year":"2025","unstructured":"Flynn KE. EXABS-112-CML: QoL: what do patients really want? Clin Lymphoma Myeloma Leuk. 2025;25:S21\u2013S2.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2826_CR25","first-page":"4887","volume":"24","author":"F Efficace","year":"2016","unstructured":"Efficace F, Breccia M, Cottone F, Okumura I, Doro M, Riccardi F, et al. Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Supportive Care Cancer. 2016;24:4887\u201394.","journal-title":"Supportive Care Cancer"},{"key":"2826_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35:626\u201330.","journal-title":"Leuk Res"},{"key":"2826_CR27","doi-asserted-by":"publisher","unstructured":"Lang F, Pemberton-Whiteley Z, Clements J, Ruiz C, Rea D, Machado L, et al. Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey. Haematologica. 2025. https:\/\/doi.org\/10.3324\/haematol.2025.287772.","DOI":"10.3324\/haematol.2025.287772"},{"key":"2826_CR28","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","volume":"3","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Adv. 2019;3:4280\u201390.","journal-title":"Blood Adv"},{"key":"2826_CR29","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00277-019-03767-y","volume":"98","author":"M Crugnola","year":"2019","unstructured":"Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, et al. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Ann Hematol. 2019;98:2329\u201338.","journal-title":"Ann Hematol"},{"key":"2826_CR30","first-page":"893","volume":"38","author":"D \u017d\u00e1\u010dkov\u00e1","year":"2024","unstructured":"\u017d\u00e1\u010dkov\u00e1 D, Semer\u00e1d L, Faber E, Klamov\u00e1 H, Stejskal L, B\u011blohl\u00e1vkov\u00e1 P, et al. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia. 2024;38:893\u20137.","journal-title":"Leukemia"},{"key":"2826_CR31","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2147\/PPA.S163393","volume":"12","author":"J Lou","year":"2018","unstructured":"Lou J, Huang J, Wang Z, Wen B, Tu C, Huang W, et al. Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey. Patient Prefer Adherence. 2018;12:1025\u201332.","journal-title":"Patient Prefer Adherence"},{"key":"2826_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2556506","volume":"30","author":"E Atallah","year":"2025","unstructured":"Atallah E, Broder MS, Chan O, Flynn KE, Gilreath JA, Hine M, et al. Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase. Hematology. 2025;30:2556506.","journal-title":"Hematology"},{"key":"2826_CR33","doi-asserted-by":"crossref","unstructured":"Maksten EF, Jensen JF, Thomsen G, Zenas DR, J\u00f8rgensen MP, Udby L, et al. Work ability in patients with chronic myeloid leukemia: a Danish nationwide cohort study. Cancers (Basel). 2025;17:1585.","DOI":"10.3390\/cancers17091585"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02826-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:05:08Z","timestamp":1767985508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02826-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2826"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02826-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PE: Consultancy: Novartis, Pfizer; Research Funding: Novartis. CL: None. ML: Research Funding: Novartis. JG: Honoraria: Novartis. PLC: Honoraria: Incyte, Blueprint, AOP, Pfizer, BMS, Novartis. THB: Consultancy: Ariad, Novartis, Pfizer, Gilead, Merck, Roche; Research Funding: Novartis, Pfizer. SS: Consultancy: Novartis, Pfizer, Roche; Research Funding: Incyte, BMS, Novartis. ABu: Honoraria: Incyte, Novartis; Research Funding: MSD, Novartis. GNF: Honoraria: Novartis, Incyte, Zentiva. PLR: Speaker: Novartis, BMS, Incyte. ABr: Honoraria: BMS, Pfizer, Consultancy: BMS, Pfizer, Travel support: BMS, Pfizer. TS: None. CF: None. TE: Research Funding: Novartis. GM: None. AH: Research support: Novartis, BMS, Pfizer, Incyte, Enliven, Terns, Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}